These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A message from the Vioxx case. Baldwin HJ; Droege M; Daniel KL Am J Health Syst Pharm; 2006 Mar; 63(6):503. PubMed ID: 16522877 [No Abstract] [Full Text] [Related]
7. Merck to pay $5bn in rofecoxib claims. Charatan F BMJ; 2007 Nov; 335(7628):1011. PubMed ID: 18006982 [No Abstract] [Full Text] [Related]
8. [Rofecoxib increases myocardial infarction risk in seniors]. Wasielewski S Med Monatsschr Pharm; 2005 Nov; 28(11):416-7. PubMed ID: 16309032 [No Abstract] [Full Text] [Related]
11. Vioxx doctors wooed by Merck are now its foes. Tesoriero HW Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911 [No Abstract] [Full Text] [Related]
12. Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx. Moynihan R BMJ; 2009 Apr; 338():b1432. PubMed ID: 19349350 [No Abstract] [Full Text] [Related]
13. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. Psaty BM; Kronmal RA JAMA; 2008 Apr; 299(15):1813-7. PubMed ID: 18413875 [TBL] [Abstract][Full Text] [Related]
14. Observational studies and the withdrawal of rofecoxib. Watson DJ; Santanello NC Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998 [No Abstract] [Full Text] [Related]
15. MI risk prompts rofecoxib withdrawal. Thompson CA Am J Health Syst Pharm; 2004 Nov; 61(21):2234-6, 2238. PubMed ID: 15552625 [No Abstract] [Full Text] [Related]
16. Bringing the FDA's Information to Market. Woloshin S; Schwartz LM Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960 [No Abstract] [Full Text] [Related]
17. Lapses at the new England journal of medicine. Smith R J R Soc Med; 2006 Aug; 99(8):380-2. PubMed ID: 16893926 [No Abstract] [Full Text] [Related]
18. [How many harmed by rofecoxib in Germany?]. Scharnetzky E; Andersohn F; Schill W; Garbe E; Pigeot I Med Klin (Munich); 2006 Aug; 101(8):675-6; author reply 678-9. PubMed ID: 17051670 [No Abstract] [Full Text] [Related]
19. Despite warnings, drug giant took long path to Vioxx recall. Berenson A; Harris G; Meier B; Pollack A N Y Times Web; 2004 Nov; ():A1, A32. PubMed ID: 15599982 [No Abstract] [Full Text] [Related]
20. NEJM stands by its criticism of Vioxx study. Tanne JH BMJ; 2006 Mar; 332(7540):505. PubMed ID: 16513694 [No Abstract] [Full Text] [Related] [Next] [New Search]